Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Apr 11, 2022
BOSTON – Since the first reports of HIV infection in the early 1980s, multiple clinical trials have tested potential vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person’s immune system from mounting an effective response following HIV vaccination. An alternative anti-HIV strategy called vectored immunoprophylaxis (VIP) designed by researchers at […]